CClinicalTrials.gg
Status unknownNCT04750291Updated Oct 22, 2021

Management of Popeye Sign With Botulinum Toxin After Bicepstenotomy

A Phase 4 interventional study of Botulinum toxin type A and Placebo in Popeye Syndrome, sponsored by AZ Delta. Status unknown at 1 site in Belgium. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-22.

Sponsored by AZ Delta · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Double-blinded randomized controlled trial with 20 people of whom 10 will receive a placebo infiltration and 10 an infiltration with botulinum toxin type A for cramping pain after arthroscopic tenotomy of the long head of the biceps tendon.

Read the detailed description

Title: Management of Popeye sign with botulinum toxin after tenotomy of the long head of the biceps tendon: a double-blinded randomized controlled trial Précis: Double-blinded randomized controlled trial with 20 people. Randomization in 2 arms of 10 people. 3 visits will be planned with a meantime of 3 months after the infiltration with botulinum toxin type A (BTX-A) or placebo that will be administered at the 2nd visit.

Objective: The primary objective is to assess the effectiveness of an infiltration with botulinum toxin in the biceps muscle after tenotomy of the long head of the biceps tendon for pain and disability reduction.

Endpoint: The primary endpoint is a pain reduction as measured by the Visual Analogue pain scale (VAS) and a reduced disability as measured by the quick DASH (Disabilities of the Arm, Shoulder and Hand).

Population: 20 people who underwent an arthroscopic tenotomy of the long head of the biceps tendon and are having post-operative pain in the biceps muscle.

Phase: 4

Number of Sites enrolling participants: single center study in AZ Delta Roeselare

Description of Study Agent: botulinum toxin type A (Botox®) 100 International Units by intramuscular injection

Study Duration: From March 2021 till December 2022

Participant Duration: 3 months

02

Conditions studied

  • Popeye Syndrome

Keywords

  • tenotomy
  • long head of the biceps tendon
  • botulinum toxin
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Have had arthroscopic tenotomy of the long head of the biceps tendon without rotator cuff repair, acromioclavicular joint resection or glenoid labrum repair
  • Having bicipital pain that started after the tenotomy

Exclusion criteria

Exclusion Criteria:

  • under 18 years of age
  • over 65 years of age
  • pregnancy or lactation
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Botulinum toxin

    Infiltration with botulinum toxin

    Drug: Botulinum toxin type A

  • Placebo comparator
    Placebo

    Infiltration with placebo or sterile saline

    Other: Placebo

Interventions

  • DrugBotulinum toxin type A

    1 infiltration in the biceps muscle with botulinum toxin (100 IU)

  • OtherPlacebo

    1 infiltration in the biceps muscle with placebo or sterile saline

05

What researchers measure

Primary outcomes

  1. Pain change

    VAS score: Visual Analogue Scale score of 0 to 10 with 0 indicating no pain and 10 the worst pain imaginable

    Time frame: 3 months

  2. Disability change

    quick DASH: Disabilities of the Arm, Shoulder and Hand 0 (no disability) to 100 (most severe disability)

    Time frame: 3 months

06

Study locations

1 of 1 sites recruiting
  • AZ Delta
    Roeselare, 8800, Belgium
    • Pieter Van Geel, MD · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04750291
Lead sponsor
AZ Delta
Responsible party
Bert VanMierlo (Principal Investigator, AZ Delta) — Principal investigator
First posted
Feb 11, 2021
Start date
Aug 9, 2021
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Oct 22, 2021

Study contacts

Pieter Van Geel, MD
Contact
pivangeel@gmail.com
+32474322540
Bert Vanmierlo, MD
principal investigator · Orthopedie Roeselare AZ Delta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion